Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Liabilities (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Total Liabilities for 7 consecutive years, with $269.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 93.94% year-over-year to $269.4 million, compared with a TTM value of $269.4 million through Dec 2025, up 93.94%, and an annual FY2025 reading of $269.4 million, up 93.94% over the prior year.
  • Total Liabilities was $269.4 million for Q4 2025 at Avidity Biosciences, up from $247.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $269.4 million in Q4 2025 and bottomed at $26.0 million in Q2 2021.
  • Average Total Liabilities over 5 years is $98.8 million, with a median of $58.2 million recorded in 2022.
  • The sharpest move saw Total Liabilities tumbled 59.65% in 2021, then soared 146.68% in 2024.
  • Year by year, Total Liabilities stood at $46.2 million in 2021, then surged by 31.58% to $60.7 million in 2022, then soared by 110.44% to $127.8 million in 2023, then increased by 8.72% to $138.9 million in 2024, then soared by 93.94% to $269.4 million in 2025.
  • Business Quant data shows Total Liabilities for RNA at $269.4 million in Q4 2025, $247.9 million in Q3 2025, and $176.3 million in Q2 2025.